Trial News & Events
AL-S Pharma announces positive topline results from Phase 2 study of AP-101 for the treatment of amyotrophic lateral sclerosis (ALS)
- Phase 2 of AP-101 in sporadic ALS and mutant SOD1-ALS met its primary safety and tolerability endpoint
Sign Up Today! Bike the US for ALS- NEALS Ride
Bike the US for ALS – 30th Anniversary Ride
Ride. Support. Make an Impact.
We invite you to join us for a special fundraising ride as we commemorate 30 years of advancing ALS research and care through NEALS.
🚴♂️ September 18–24, 2025
📍 Route: GAP and C&O Trail (Pittsburgh, PA → Washington, D.C.)
🎯 Fundraising Goal: $5,000 per rider
Qalsody Conditionally Approved in Canada for ALS Linked to SOD1 Gene Mutations
QALSODY™ (tofersen injection) Receives Conditional Marketing Authorization from Health Canada as the First ALS Treatment Targeting a Genetic Cause
Groundbreaking Directive Ensures ALS Patients on Medicare Advantage Gain Access to Qalsody
The Centers for Medicare & Medicaid Services (CMS) has announced a first-of-its-kind directive requiring Medicare Advantage plans to approve coverage for Qalsody, a treatment for people living with genetic SOD1-ALS. This decision reflects the ALS Association’s commitment to ensuring that people living with ALS have access to promising ALS treatments without delay.
